Clinical Trials Browser

Active not recruiting × Brain Neoplasms × pembrolizumab × Clear all

NCT02359565 2026-03-18

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

NCT03277638 2026-01-08

Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)

Phase 1/2 Active not recruiting

32 enrolled

CNS

Brain Neoplasms, Glioblastoma

NCT05341349 2025-07-30

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Phase 1 Active not recruiting

1 enrolled

CNSDermatologic

Uveal Melanoma, Brain Neoplasms, Melanoma

NCT02852655 2025-03-13

A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

Phase 1 Active not recruiting

60 enrolled 19 charts

CNS

Brain Neoplasms

NCT04074096 2024-06-03

BEPCOME-MB

Phase 2 Active not recruiting

10 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02886585 2024-03-12

Pembrolizumab In Central Nervous System Metastases

Phase 2 Active not recruiting

101 enrolled

CNS

Brain Neoplasms